Roche Pharmaceuticals announced on April 11 that Elecsys pTau217, the company's plasma biomarker to support early Alzheimer's disease diagnosis, has been certified as a breakthrough device by the US Food and Drug Administration (FDA). The test method was developed by Eli Lilly in collaboration with Roche, and it will be used to help determine whether amyloid pathology is present in an individual's body and help diagnose the patient's disease.
罗氏与礼来合作的阿尔茨海默病检测法获得美国FDA突破性设备认定
Roche's and Eli Lilly's Alzheimer's disease testing method was recognized as a breakthrough device by the US FDA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.